- Home
- AHG vs INBX Comparison
AHG vs INBX Comparison
Compare AHG & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AHG | INBX |
|---|---|---|
| Founded | 2013 | 2010 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 999.7M |
| IPO Year | 2017 | 2024 |
Fundamental Metrics
Financial Performance| Metric | AHG | INBX |
|---|---|---|
| Price | $2.31 | $58.86 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 32.1K | ★ 143.2K |
| Earning Date | 08-14-2025 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,300,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 550.00 |
| 52 Week Low | $0.83 | $10.81 |
| 52 Week High | $2.50 | $94.57 |
Technical Indicators
Market Signals| Indicator | AHG | INBX |
|---|---|---|
| Relative Strength Index (RSI) | 65.56 | 33.28 |
| Support Level | $1.40 | $28.54 |
| Resistance Level | N/A | $85.97 |
| Average True Range (ATR) | 0.29 | 4.27 |
| MACD | 0.01 | -0.55 |
| Stochastic Oscillator | 88.48 | 8.45 |
Price Performance
Historical ComparisonAbout AHG Akso Health Group ADS
Akso Health Group is a social e-commerce platform based in China. The company collaborates with domestic e-commerce platforms and offers users a wide selection of high-quality and affordable products on its social e-commerce platform. It generates majority of the revenues from sale of medical devices business.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.